Leqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease, with confirmed presence of amyloid pathology in the brain.

Amyloid beta-directed antibody.

The terminal half-life is approximately 5 to 7 days. It is primarily distributed in the vascular space and cleared by proteolytic degradation.

Serious hypersensitivity to lecanemab-irmb or to any of its excipients.

There are no adequate data on the developmental risk associated with the use of Leqembi in pregnant women.

There are no data on the presence of lecanemab-irmb in human milk, the effects on the breastfed infant, or the effects on milk production.

Amyloid Related Imaging Abnormalities (ARIA), including ARIA-E (edema) and ARIA-H (hemorrhage); Infusion-related reactions; Headache.

Intravenous infusion: 10 mg/kg administered once every two weeks. The infusion duration is approximately 1 hour.

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Store in original carton to protect from light. Do not freeze or shake.